376 Index Name Paper ref. Name Paper ref. Vyslouzil, L Tue 342 Waako, P Tue 005, Wed 136, FC01.4.5 Wachall, B Thu 010 Wacheck, V W05.3 Waddington, J L FC17.2.1 Wade, JD Wed 080 Wade, R Tue 353 Wade, S Thu 044 Wadi, N Tue 152 Wadie, W Wed 382 Wadsworth, R Thu 272 Waeckel, L Thu 273, Thu 274 Wagg, C FC05.2.6 Wagner, M Tue 166 Wainwright, C Tue 232, Mon 211 Wake, H Tue 272, Mon 035, Mon 329, Thu 275 Wakita, S Mon 464 Wakuda, H Tue 067, Tue 143 Waldhoer, M FC11.1.6, Wed 073, Thu 078 Waldkirch, E FC08.3.5, Tue 212 Wallace, E Thu 030 Walsh, D Tue 090 Walsh, MP Wed 239 Walsh, S FC14.1.1 Walsh, TS Thu 420, Tue 270 Walter, M Thu 112 Walter, Nicole Tue 438 Walters, MR FC15.1.6 Walubo, A FC01.1.1 Walubo, A Mon 258, Wed 389, Wed 390, Wed 391 Wan Aasim, WR Tue 153 Wang, C Tue 325 Wang, A-Y Tue 400 Wang, B Mon 228 Wang, B-S Thu 368 Wang, C Tue 163, Mon 468, Tue 412, Tue 173, Mon 467, Mon 408, Wed 327, Wed 150, Tue 152 Wang, C-B Mon 008 Wang, C Mon 414 Wang, C Tue 033 Wang, C-Y Mon 423 Wang, D Tue 135 Wang, D Thu 103, Tue 068 Wang, F Tue 138, Thu 367 Wang, G FC12.4.5, Wed 378, Mon 092 Wang, G-L FC16.4.5, Wang, H Wed 242, Tue 138, Mon 458 Thu 089, Thu 368 Wang, HC Mon 356 Wang, J Tue 425, Wed 270, FC15.4.6, Thu 088, Tue 284, Tue 371 Wang, J Tue 439 Wang, K Thu 172, Tue 307 Wang, L Thu 017, Mon 056, Tue 069, Tue 070, Mon 466, Mon 445, Tue 440, Tue 155, Tue 317, Tue 183 Wang, LL Thu 276 Wang, M Tue 070 Thu 340 Wang, P Thu 370, Thu 306, Thu 210, Thu 369 Wang, Q Mon 331, Thu 089 Wang, Q-G Thu 375 Wang, R FC15.3.6 Wang, S Tue 389 Wang, S Tue 034 Wang, S-P Thu 277 Wang, T FC12.2.5 Wang, Tao Mon 465 Wang, W Thu 378 Wang, W Thu 370 Wang, X Thu 371, Wed 378, Mon 445 Thu 378 Wang, X Mon 466 Wang, X-J Wed 367 Wang, XX FC18.4.5 Wang, Y YI.06 , FC12.2.5, Wed 331, Mon 034, Thu 372, Thu 020, Thu 270, Tue 035, Wed 039, Thu 340 Wang, Yn Tue 285 Wang, Y-H Tue 187, Tue 186 Thu 277 Wang, Y Thu 104 Wang, Y-W Wed 328 Wang, YX Tue 082 Wang, Z Tue 286, Thu 445 Wang, Z-J FC03.3.3 Wannarat, K Thu 356 Ward, M Tue 495 Ward, MB Tue 066 Ward, R FC03.2.6 Warner, T FC09.4.1 Warner, TD Thu 200 Warren, S Tue 145 Warstat, C Tue 238 Wasilewski, R Mon 181 Wasner, G W03.6 Watanabe, A Tue 234 Watanabe, H W23.1, W23.4, Mon 093, Tue 144, Tue 473, Thu 262 Watanabe, M Mon 253, Wed 117, Tue 273, Tue 380, Tue 492 Watanabe, T Tue 459, Wed 414 Watanabe, Y Tue 071, Tue 244 Watanabe, Y Tue 377 Watanabe, Y Tue 154 Watanabe, Y Tue 287 Watanuki, S Tue 166 Waterhouse, C Tue 229 Waters, N Wed 147 Waters, S Wed 147 Watier, H Mon 363 Watson, A Thu 228 Watson, JM Wed 030 Watt, S Mon 211 Watts, A Thu 085 Wawruch, M Tue 113 Waxman, SG FC03.1.4, FC12.2.1 Webb, DJ FC15.3.5, Thu 420, Tue 270 Webb, T Tue 037 Weber, C W09.2, Thu 240 Weber, G Mon 479, Thu 354 Weber, M-A FC12.2.3 Webster, R Mon 236 Weerasuriya, K FC01.2.2, W36.1, W36.6
Name Paper ref. Name Paper ref. Wegener, G Wed 399, Thu 405 Wei, J Thu 262 Wei, W Tue 288 Weihe, P Wed 151 Weikop, P FC02.3.6 Weimann, A Mon 406 Weinberg, PD Thu 238 Weinshilboum, RM FC13.5.4 Weinstein, H FC02.1.2, FC02.3.5, Mon 073 Weiser, D Wed 382, Mon 317, Thu 317, Wed 417, Tue 462 Welch, S Tue 064 Wellendorph, P FC11.5.1, FC11.5.6 Welling, J FC16.3.4 Wells, P Tue 301 Wells, TNC W31.1 Welscher, U Mon 479, Thu 211, Tue 214, Mon 245 Welsh, D Thu 105 Wen, H Thu 278 Wen, M Mon 310 Wenceslau, C Wed 042 Wendling, D Tue 198 Wendremaire, M Tue 289, Tue 290 Wenger, C Thu 435 Wennerberg, M Thu 426 Wergin, K Wed 119 Werner, B Tue 151 Werner, M YI.05 Werner, M Thu 279 Westfall, T Tue 205, Tue 206, Tue 204, Mon 244 Westley, I Tue 495 Weston, AH FC15.2.1, Wed 269, Wed 238 Weston, R FC03.1.6 Wettstein, JG Wed 094 Wheat, A Wed 392 Whistler, J Wed 073 White, C Tue 215 White, P Thu 032 White, P W20.1, Thu 280 Whittard, J FC14.1.2 Wiborg, O Mon 046, Wed 433, Wed 397 Wibral, M FC17.2.2 Wichmann, J Wed 094 Wicklund, B FC13.3.5 Widmann, C FC17.2.5, Thu 237 Wiench, M FC18.4.2 Wieninger, PR Mon 153 Wiesen, M Thu 018 Wietzorrek, G Tue 151 Wigerinck, P Tue 280 Wihl, J Tue 395 Wijtmans, M Thu 060 Wikström, S Thu 008 Wilding, JPH FC05.1.3 Wilkes, DK Mon 442 Wilkowski, R Tue 214 Willars, GB Wed 025 Williams, D Tue 063, Tue 495 Williams, JHG Tue 109 Williams, P Thu 110 Williams, R Thu 393 Wilm, S Tue 108 Wilson, C Mon 339 Wilson, J X W04.1.4 Wingler, K FC15.4.4 Wink, D FC09.3.3 Winkelmayer, WC Mon 153 Wirth, A Wed 056, Tue 134 Wirth, VF Thu 086 Wise, H Mon 321, Thu 045 Wissel, G Wed 088 Witschi, R FC03.3.3 Wittkopf, D Thu 087 Wlash, EJ Wed 239 Wojnowski, L FC02.1.5 Wolber, G Thu 014 Woldbye, D FC02.3.6 Wölfling, J Thu 308 Wolin, MS FC08.2.5 Wolmarans, DW Thu 428 Woltering, T Wed 094 Wolzt, M W10.1 Won, H-H Tue 335 Wong, CCM W02.1.4, Tue 476 Wong, DVT Tue 255 Wong, ESW Thu 281 Wong, M SK Thu 282 Wong, SL FC15.4.7 Wong, WT FC15.4.7 Wong, Y-H Thu 045 Wongkajornsilp, A Mon 334 Wood, Ruth I FC14.5.3 Woodman, OL Wed 288, Wed 289 Woodward, D Wed 270 Woodward, D Thu 088, Tue 284 Woolf, CJ FC03.3.4 Wootten, D Wed 082 Worku, A FC01.4.7, Mon 018 Wörtwein, G FC02.3.6 Wotjak, C FC17.5.5 Wotjak, CT Thu 396 Wraber, B Wed 178 Wright, C Mon 214 Wright, J Tue 309 Wright, K Tue 460 Wright, WR Thu 241 Wu, B-N Thu 105 Wu, C Tue 299, Thu 367, Tue 440, Tue 155 Wu, C-C Wed 222, Thu 283 Wu, CL Thu 429 Wu, C-S Wed 430 Wu, J Thu 445 Wu, J Thu 089 Wu, JY Mon 032 Wu, K Wed 099 Wu, L Tue 130 Wu, M Tue 382 Wu, N Thu 171, FC14.5.4 Wu, Q Tue 184, Tue 458, Thu 186, Tue 178, FC14.4.6, Tue 382, Tue 181, Thu 116, Thu 184, Thu 182, Thu 185 Wu, W-B Thu 373 Wu, Y Thu 388 Index 377
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309:
FC16 Natural products: Past and fut
- Page 310 and 311:
FC16 Natural products: Past and fut
- Page 312 and 313:
FC17 New approaches and targets in
- Page 314 and 315:
FC18 Nuclear receptor targets for t
- Page 316 and 317:
314 Index Name Paper ref. Name Pape
- Page 318 and 319:
316 Index Name Paper ref. Name Pape
- Page 320 and 321:
318 Index Name Paper ref. Name Pape
- Page 322 and 323:
320 Index Name Paper ref. Name Pape
- Page 324 and 325:
322 Index Name Paper ref. Name Pape
- Page 326 and 327:
324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor